Gary A. Lyons, a director at Travere Therapeutics (TVTX), sold 8,000 shares of common stock for approximately $329,000 on April 14, 2026, following the exercise of stock options. This transaction reduced his direct holdings by 12.21%, leaving him with 57,500 shares valued at around $2.42 million. Notably, this sale occurred just after the FDA granted full approval for Travere’s FILSPARI, the first approved treatment for focal segmental glomerulosclerosis (FSGS), which opens a significant new market opportunity.
The timing of this transaction is critical for investors, as FILSPARI’s approval adds to Travere’s existing revenue streams from other rare disease therapies. The company reported a 144% year-over-year increase in net product sales for FILSPARI, totaling $322 million for 2025, while achieving a non-GAAP net income of $81.1 million, a stark contrast to the previous year’s loss.
For market professionals, the key takeaway is that while Lyons’ share sale may seem modest, it coincides with a pivotal moment for Travere as it expands its commercial footprint and continues to demonstrate strong revenue growth. The successful launch of FILSPARI will be crucial for sustaining this momentum.
Source: fool.com